Circadian disruption and cancer risk: A new concept of stromal niche (Review)

International Journal of Oncology

Volumn 44, Issue 2, 2014, Pages 364-370

  Izumi, Hiroto ^a   Wang, Keyong ^b   Morimoto, Yasuo ^a   Sasaguri, Yasuyuki ^c   Kohno, Kimitoshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Bio information Research Center   (Japan)

^c Center for Promotion of Clinical and Translational Research   (Japan)

Author keywords

Cancer stem cell; Cancer associated fibroblast; Circadian disruption; Stromal niche; WNT10A

Indexed keywords

ANTINEOPLASTIC AGENT; WNT10A PROTEIN;

CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER RISK; CANCER STEM CELL; CARCINOGENESIS; CELL PROTECTION; CELL SURVIVAL; CIRCADIAN RHYTHM; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; STEM CELL NICHE; STROMA; STROMA CELL; STROMAL NICHE; TUMOR MICROENVIRONMENT;

ANIMALS; CHRONOBIOLOGY DISORDERS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; RISK FACTORS; STEM CELL NICHE; STROMAL CELLS;

EID: 85047689299     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2201     Document Type: Review

References (41)

1. Antoni MH, Lutgendorf SK, Cole SW, et al: The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6: 240-248, 2006. (Pubitemid 43292567)
2. Lutgendorf SK, Sood AK and Antoni MH: Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol 28: 4094-4099, 2010.
3. Costa G, Haus E and Stevens R: Shift work and cancer-considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health 36: 163-179, 2010.
4. Kolstad HA: Nightshift work and risk of breast cancer and other cancers - a critical review of the epidemiologic evidence. Scand J Work Environ Health 34: 5-22, 2008.
5. McGregor BA and Antoni MH: Psychological intervention and health outcomes among women treated for breast cancer: a review of stress pathways and biological mediators. Brain Behav Immun 23: 159-166, 2009.
6. Fu L and Lee CC: The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3: 350-361, 2003. (Pubitemid 37328855)
7. Yu EA and Weaver DR: Disrupting the circadian clock: genespecific effects on aging, cancer, and other phenotypes. Aging (Albany, NY) 3: 479-493, 2011.
8. Borovski T, De Sousa E Melo F, Vermeulen L and Medema JP: Cancer stem cell niche: the place to be. Cancer Res 71: 634-639, 2011.
9. Li L and Xie T: Stem cell niche: structure and function. Annu Rev Cell Dev Biol 21: 605-631, 2005. (Pubitemid 41740648)
10. McAllister SS and Weinberg RA: Tumor-host interactions: a far-eaching relationship. J Clin Oncol 28: 4022-4028, 2010.
11. Lu P, Weaver VM and Werb Z: The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196: 395-406, 2012.
12. Provenzano PP, Inman DR, Eliceiri KW, et al: Collagen density promotes mammary tumor initiation and progression. BMC Med 6: 11, 2008.
13. Coghlin C and Murray GI: Current and emerging concepts in tumour metastasis. J Pathol 222: 1-15, 2010.
14. Zhou Y, Yan H, Guo M, et al: Reactive oxygen species in vascular formation and development. Oxid Med Cell Longev 2013: 374963, 2013.
15. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
16. Kohno K, Uchiumi T, Niina I, et al: Transcription factors and drug resistance. Eur J Cancer 41: 2577-2586, 2005. (Pubitemid 41540632)
17. Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 6: 392-401, 2006.
18. Cirri P and Chiarugi P: Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 31: 195-208, 2012.
19. Bhowmick NA, Neilson EG and Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337, 2004. (Pubitemid 39551661)
20. Karnoub AE, Dash AB, Vo AP, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007. (Pubitemid 47525152)
21. Mishra PJ, Mishra PJ, Humeniuk R, et al: Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68: 4331-4339, 2008.
22. Quante M, Tu SP, Tomita H, et al: Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19: 257-272, 2011.
23. Liu S, Ginestier C, Ou SJ, et al : Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71: 614-624, 2011.
24. Cabarcas SM, Mathews LA and Farrar WL: The cancer stem cell niche - there goes the neighborhood? Int J Cancer 129: 2315-2327, 2011.
25. Yasuniwa Y, Izumi H, Wang KY, et al: Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway. PLoS One 5: e15330, 2010.
26. Fodde R and Brabletz T: Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 19: 150-158, 2007. (Pubitemid 46386404)
27. Pagès F, Galon J, Dieu-Nosjean MC, et al: Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29: 1093-1102, 2010.
28. Mantovani A, Germano G, Marchesi F, et al: Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 41: 2522-2525, 2011.
29. Bateman A: Growing a tumor stroma: a role for granulin and the bone marrow. J Clin Invest 121: 516-519, 2011.
30. Bohring A, Stamm T, Spaich C, et al: WNT10A mutations are a frequent cause of a broad spectrum of ectodermal dysplasias with sex-biased manifestation pattern in heterozygotes. Am J Hum Genet 85: 97-105, 2009.
31. Russell SB, Russell JD, Trupin KM, et al : Epigenetically altered wound healing in keloid fibroblasts. J Invest Dermatol 130: 2489-2496, 2010.
32. Schäfer M and Werner S: Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 9: 628-638, 2008.
33. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L and Reiter RJ: Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 17: 4462-4481, 2010.
34. Torigoe T, Izumi H, Ishiguchi H, et al: Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5: 15-27, 2005. (Pubitemid 40081291)
35. Tanabe M, Izumi H, Ise T, et al : Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 63: 8592-8595, 2003. (Pubitemid 38064031)
36. Igarashi T, Izumi H, Uchiumi T, et al: Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26: 4749-4760, 2007. (Pubitemid 47093179)
37. Miyamoto N, Izumi H, Miyamoto R, et al: Transcriptional regulation of activating transcription factor 4 under oxidative stress in retinal pigment epithelial ARPE-19/HPV-16 cells. Invest Ophthalmol Vis Sci 52: 1226-1234, 2011.
38. Miyamoto N, Izumi H, Noguchi T, et al: Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 283: 18218-18226, 2008.
39. Lévi F, Okyar A, Dulong S, Innominato PF and Clairambault J: Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50: 377-421, 2010.
40. Sun Y, Campisi J, Higano C, et al: Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18: 1359-1368, 2012.
41. Guo B, Chatterjee S, Li L, et al: The clock gene, brain and muscle Arnt-like 1, regulates adipogenesis via Wnt signaling pathway. FASEB J 26: 3453-3463, 2012.